Key result
Lipid-modulating agents show no reported clinical benefit across 40 trials for COVID-19.
Systematic Review
Answers are grounded in this paper and cite their sources.
Coronavirus disease 2019 (COVID-19) is associated with systemic inflammation, endothelial activation, and multi-organ manifestations. Lipid modulating agents may be useful in treating patients with COVID-19. They may inhibit viral entry by lipid raft disruption or ameliorate the inflammatory response and endothelial activation. In addition, dyslipidemia with lower high-density lipoprotein cholesterol and higher triglycerides portends worse outcome in patients with COVID-19. Upon a systematic search, 40 RCTs with lipid modulating agents were identified, including 17 statin trials, 14 omega-3 fatty acids RCTs, 3 fibrates RCTs, 5 niacin RCTs, and 1 dalcetrapib RCT for management or prevention of COVID-19. This manuscript summarizes the ongoing or completed randomized controlled trials (RCTs) of lipid modulating agents in COVID-19 and the implications of these trials for patient management.
No takes yet. Share an insight, caveat, or question.
Talasaz et al. (2021) conducted a systematic review in COVID-19. Lipid-modulating agents (statins, omega-3 fatty acids, fibrates, niacin, dalcetrapib) was evaluated. A systematic search identified 40 randomized controlled trials evaluating various lipid-modulating agents for the prevention or treatment of COVID-19, with no specific clinical outcomes reported in the abstract.